INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext....
Covered in this story
Analyst targets on Boston Scientific
- Truist Securities: at $42.7 · target $51 by Oct 2027 · Buy via Investing.com
- RBC Capital Markets: at $42.7 · target $52 by Oct 2027 · Outperform via Investing.com
- Canaccord Genuity: at $42.7 · target $48 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BSX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Boston Scientific →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.